Abstract:Introduction Elevated C-reactive protein (CRP) levels are often present in individuals with atherosclerotic cardiovascular disease (ASCVD), including in those who also have chronic kidney disease (CKD), and are associated with an increased risk of major adverse cardiovascular events (MACE). To understand unmet needs in the identification and management of at-risk individuals, we characterized patients with ASCVD in a UK database, according to CKD stage and CRP levels. Methods This study comprised separate retrospective cross-sectional and longitudinal cohort analyses of patients in the Clinical Practice Research Datalink (CPRD) Aurum database, a representative UK database of anonymized primary care records. In the cross-sectional analysis, CPRD Aurum was linked with Hospital Episode Statistics (HES) and Index of Multiple Deprivation data to assess patient characteristics on 1 Jan 2021 (defined as index date). In the cohort analysis, CPRD Aurum was linked with HES and Office for National Statistics mortality data to determine the incidence of 3-point MACE (3P-MACE) over approximately 5 years of follow-up (index date: 1 Jan 2016). Both analyses included individuals ≥ 18 years old with an ASCVD diagnosis in both primary and secondary care in the 5 years pre-index. Data were analysed using descriptive statistics. Patient characteristics were assessed by CKD stage; for individuals with CKD stage 3–4, characteristics were also assessed by CRP levels. Results In total, 225,767 and 230,055 individuals were included in the cross-sectional and cohort analyses, respectively. The prevalence of CKD stage 3–4 among individuals with ASCVD was 24.3% (Table 1). The proportion of individuals with elevated CRP (CRP ≥ 2 mg/L) and anaemia increased for successively higher CKD severity groups; in addition, glycated haemoglobin (HbA1c) ≥ 7% and elevated blood pressure were generally more frequently observed in individuals with CKD than in those without (Table 1). Individuals with ASCVD, CKD stage 3–4 and elevated CRP had higher HbA1c and total cholesterol levels and a greater proportion had obesity, anaemia and elevated blood pressure, compared with individuals with CRP < 2 mg/L (Table 2). Over 5 years' follow-up, the incidence of 3P-MACE increased with CKD severity (Table 1) and with increasing CRP levels in individuals with ASCVD and CKD stage 3–4 (Table 2). However, only 28% of individuals with ASCVD and CKD stage 3–4 had CRP measurements. Conclusion Adults with ASCVD, CKD and elevated CRP identified from primary and secondary UK care records had a higher disease burden than individuals with CRP levels < 2 mg/L. In the UK, testing CRP levels is not routinely recommended, resulting in a high proportion of missing CRP measurements in this study. Routine testing of CRP may help in identifying patients with residual cardiovascular risk and has the potential to support risk assessment and management of patients with ASCVD and CKD.

In which common chronic conditions can (or cannot) obesity and lifestyle factors explain higher concentrations of C‐reactive protein?

Association Between C-reactive Protein, Incident Liver Cancer, and Chronic Liver Disease Mortality in the Linxian Nutrition Intervention Trials: a Nested Case-Control Study.

Association between C-Reactive protein and periodontitis in an obese population from the NHANES 2009-2010

A Cross-Sectional Study of Korean Adults Using High-Sensitivity C-Reactive Protein as a Biomarker

Characterization of individuals with atherosclerotic cardiovascular disease, with and without chronic kidney disease: results from a UK electronic health record database

Genetically Determined Chronic Low-Grade Inflammation and Hundreds of Health Outcomes in the UK Biobank and the FinnGen Population: A Phenome-Wide Mendelian Randomization Study

C-reactive protein, obesity, atopy and asthma symptoms in middle-aged adults

The impact of inflammation on the obesity paradox in coronary heart disease

Obesity aggravates the role of C‐reactive protein on knee pain: A cross‐sectional analysis with NHANES data

Altered anthropometrics and HA1c levels, but not dyslipidemia, are associated with elevated hs-CRP levels in middle-aged adults: A population-based analysis

Systemic inflammation among adults with diagnosed and undiagnosed cardiometabolic conditions: a potential missed opportunity for cardiovascular disease prevention

C-reactive Protein and Risk of OSA in Four US Cohorts.

Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort

Burden of systemic inflammation and associated health outcomes in adults with atherosclerotic cardiovascular disease managed in routine care

C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project

Associations of C-Reactive Protein with 14 Cardiovascular Diseases: an Observational and Mendelian Randomization Study

The association between inflammatory biomarkers and metabolically healthy obesity depends of the definition used

Area-Level Socioeconomic Status, Adiposity, Physical Activity, and Inflammation in Young Adults, 2013

Synergistic Effects of Overweight/obesity and High Hemoglobin A1c Status on Elevated High-Sensitivity C-reactive Protein in Chinese Adults: a Cross-Sectional Study.

Lifestyle Determinants of C-Reactive Protein in Middle-Aged, Urban Chinese Men

Mortality risk among adult americans living with cancer and elevated CRP